When science, policy, and investing converge... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

Loyal reader since November 2024

View in browser EDITOR'S NOTE There's a seismic shift coming to the healthcare space - and savvy investors need to be watching it closely. On April 30, a Medicare decision linked to the H.R. 2407 bill in Congress could pave the way for nationwide coverage of a game-changing cancer screening test. The real story? A $1.1 billion microcap firm is already steps ahead - with exclusive patents, a vast DNA database, and a direct partnership with Medicare. If coverage is approved, this company could see explosive growth, becoming a leader in early cancer detection and delivering extraordinary returns to early investors. Trust me, you'll want to check out this opportunity before the mainstream press catches on. Click here now to view the urgent briefing before April 30. - Nicole Labra, Senior Managing Editor THE SHORTEST WAY TO A RICH LIFE A Rare Moment of Alignment in Washington Rachel Gearhart, Publisher, The Oxford Club It's not often that Washington D.C., Wall Street, and medical innovation all align at the same time. But that's exactly what's happening right now... and savvy investors who recognize this rare setup could experience one of the most lucrative opportunities of the decade. It all centers around a groundbreaking new bill quietly advancing through Congress, called H.R. 2407. At first glance, it looks like a run-of-the-mill Medicare policy update. But if you dig deeper, you'll see something noteworthy... A legislative green light that could give more than 60 million seniors access to a revolutionary early cancer detection test. This test doesn't require invasive scans or procedures. A simple blood draw that could detect cancer at Stage 1, when treatment success rates skyrocket. For families across America, this could be life saving. But for early investors who know where to look, it could also be a once-in-a-generation chance to profit from the biggest medical breakthrough of 2025. SPONSORED AI Boom's Secret Winners The company top investors say it could become "the most valuable business on the planet"... overtaking Nvidia. More Details Here The Stock Hiding Behind the Headline Chief Investment Strategist Alexander Green has been tracking this story for months... While most are focused on the bill itself, Alex has zeroed in on a single company he believes is positioned to benefit the most. This company is small - sporting a $1.1 billion market cap. But its potential is enormous. This company is already... Running a 50,000-patient trial in collaboration with Medicare Sitting on what may be the world's largest cancer DNA database And protecting its test with a suite of patents on proprietary "Stage 1" detection tech. Before the bill even passes, this company could secure exclusive access to the Medicare market through a rarely used policy shortcut called "coverage with evidence development." That would make it the de facto leader in cancer screening for America's seniors - a market that could be worth billions in annual revenue. And based on our research, that could send the stock soaring by 50X or more in the years ahead. SPONSORED "The question isn't whether I should invest... It's HOW MUCH should I invest?" - Billionaire Ray Dalio Have you heard the rumor about Charlie Munger's final investment? Munger's close associate, billionaire investor Mohnish Pabrai, says it could be "the most valuable business on the planet", surpassing Nvidia. And right now, you can get in with as little as $50. CLICK HERE FOR THE FULL STORY Why Timing Is Everything This is one of those rare setups where policy, innovation, and investor timing all converge. Congress is expected to move forward with H.R. 2407 in the coming weeks. When it does, headlines will spread. Analysts will scramble. And institutional money will likely rush into this tiny stock. By then, the biggest gains will be gone. That's why we've published an urgent investor briefing detailing everything you need to know about the test, the bill, and the small cap company that could soon dominate this high-stakes corner of the healthcare world. As Alex said in a recent note to Members... "Most investors will see a Medicare bill. But if you look closer, you'll see a potential 5,000% profit window opening up - and possibly closing just as fast." The early data is compelling. The timing is urgent. And if this company's tech becomes the Medicare standard, early investors could look back on this moment as the decision that changed everything. Click here now to watch our exclusive briefing and get the name of the company before the story breaks. To your health and wealth, Rachel BUILD AND PROTECT YOUR WEALTH Why This Billionaire's Multimillion-Dollar Bet on a Little-Known AI Stock Could Be Your Next Payday! "NFLX's hourly squeeze, stacked EMAs, and relative strength make it a perfect pre-earnings momentum trade." He Called Apple, Amazon, Netflix, and Nvidia Over 20 Years Ago. Now He Says to Buy AI's "Next Magnificent Seven" Stocks. "This latest AI initiative is big news for companies like RXRX." JOIN THE CONVERSATION Facebook LinkedIn Email Share MORE FROM LIBERTY THROUGH WEALTH The World's Simplest Portfolio Investing Doesn't Get Any Simpler Than This What is Dr. Copper Telling Us Now? Three Smart Moves to Make When Chaos Hits the Markets SPONSORED Yours Free! Top FIVE Dividend Stocks Right Now Marc Lichtenfeld - income expert and author of Get Rich with Dividends - is giving away his Ultimate Dividend Package... completely free of charge! You'll discover... An "A"-rated, ultra-safe dividend stock with a huge 8% yield Three of Marc's favorite "Extreme Dividend" stocks, which could supercharge your income And finally, Marc's No. 1 dividend stock for a LIFETIME of income. Click here to get the names and ticker symbols now... before the download link expires. **NO CREDIT CARD REQUIRED!** You are receiving this email because you subscribed to Liberty Through Wealth. Liberty Through Wealth is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Liberty Through Wealth | Unsubscribe © 2025 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.806.4508 | International: +1.443.353.4610 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.